Time filter

Source Type

ONCODESIGN (Paris:ALONC) (FR0011766229 - ALONC), société biotechnologique au service de l’industrie pharmaceutique pour la découverte de nouvelles molécules thérapeutiques contre les cancers et autres maladies graves sans traitement efficace connu, annonce être entrée en phase de négociation exclusive pour l’acquisition des activités de services en Métabolisme, Pharmaco-cinétique, Bioanalyse et Médecine Translationnelle de Bertin Pharma. Ces activités dans les domaines de l’immunologie et de l’infectiologie, viendraient compléter idéalement l’offre actuelle de services du groupe Oncodesign. Créée il y a plus de 20 ans par le Dr. Philippe Genne, PDG et actionnaire principal, Oncodesign est une entreprise biotechnologique qui maximise les chances de succès de l’industrie pharmaceutique pour découvrir de nouvelles molécules thérapeutiques contre les cancers et autres maladies graves sans traitement efficace connu. Fort d’une expérience unique acquise auprès de plus de 600 clients, dont les plus grandes entreprises pharmaceutiques du monde, et s’appuyant sur une plateforme technologique complète, alliant chimie médicinale, pharmacologie et imagerie médicale de pointe, Oncodesign est en mesure de prédire et d’identifier, très en amont, pour chaque molécule son utilité thérapeutique et son potentiel à devenir un médicament efficace. Appliquée aux inhibiteurs de kinases, des molécules qui représentent un marché estimé à plus de 46 milliards de dollars en 2016 et près de 25% des investissements en R&D de l’industrie pharmaceutique, la technologie d’Oncodesign a déjà permis de cibler plusieurs molécules d’intérêts à fort potentiel thérapeutique, en oncologie et hors-oncologie, et de signer des partenariats avec des groupes pharmaceutiques tels que Bristol-Myers Squibb et UCB. Basée à Dijon, au cœur du pôle universitaire et hospitalier et au sein du cluster de Paris-Saclay, Oncodesign compte 165 collaborateurs et dispose de filiales au Canada et aux États-Unis.


ONCODESIGN (Paris:ALONC) (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has announced the opening of a period of exclusive negotiations to acquire Bertin Pharma's service businesses in Metabolism, Pharmacokinetics, Bio-analysis and Translational Medicine. These activities in the fields of immunology and infectiology will be an ideal fit with Oncodesign group's current service offering. The business portfolio under discussion has some 48 employees, with 2016 revenue of €5.3 million. It complements Oncodesign in many technological and regulatory areas and would contribute to the acceleration of Oncodesign group's 2017-2020 strategic plan for its service business. This project, which has been the subject of an information and consultation process with employee representative bodies, could be completed in the summer of 2017. At present it is not certain that any agreement will be reached nor that the transaction will be completed. No further comment will be made until an agreement is finalized. Founded over 20 years ago by Dr Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biotechnology company that maximises the pharmaceutical industry’s chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment. With its unique experience acquired by working with more than 600 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modelling and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB. Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 165 employees and subsidiaries in Canada and the USA.


Patent
Oncodesign | Date: 2014-03-14

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.


Patent
Oncodesign | Date: 2014-03-14

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.


Patent
Oncodesign | Date: 2015-06-19

The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.


Patent
Oncodesign and Ipsen | Date: 2012-09-28

The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinsons disease and Alzheimers disease.


Patent
Oncodesign | Date: 2012-09-28

The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.4.1-2 | Award Amount: 3.92M | Year: 2012

Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patients survival.Currently-used drugs target both MM cells (MMC) and cells of the bone marrow (BM) microenvironment or niche that are critical for supporting MMC survival, proliferation and growth. Since patients repeatedly relapse after such treatments, the following mechanisms of relapse are considered and need to be investigated: i) drugs have spared specific subclones or subpopulations of MMC ii) drugs induce alterations in cells of the niche that promote drug-resistance. OVER-MYR integrates a network of outstanding researchers from 6 EU countries with internationally recognized experience in clinics and human and animal models of MM, who will jointly: WP1: Study the molecular alterations in primary MM and environment cells in samples obtained from a large number of patients at treatment inclusion and relapse, using high throughput techniques. WP2: Implement in vitro and in vivo models of drug resistance to evaluate molecular and cellular mechanisms and compare their characteristics with drug resistant cells isolated from patients. Combined results of WP1 and WP2 will permit the identification of 10 prominent (altered) candidate genes involved in MM relapse. Changes in drug resistance, cell survival and proliferation will be assessed in WP2 by modulating the expression of the selected genes. WP3: Determine how cells from the niche alter their functions in the presence of drugs, and how drug-altered cells impact on MM cells during therapy. WP4: Screen chemical libraries for drugs active on generated sensitive cell lines, develop innovative inhibitors and provide proof of principle for a phase I/II trial


Patent
Ipsen and Oncodesign | Date: 2014-03-14

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 kinase, for use in the diagnosis, prevention and/or treatment of LRRK2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent. Finally, the present invention also relates to new macrocyclic compounds.


Patent
Ipsen and Oncodesign | Date: 2015-06-23

The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinsons disease and Alzheimers disease.

Loading Oncodesign collaborators
Loading Oncodesign collaborators